Dr. Nipunika Somatilaka publishes her manuscript reporting on STING/ICB for MPNST in the Journal of Clinical Investigation.

Dr. Somatilaka’s studies showed that STING agonist treatment of malignant peripheral nerve sheath tumors (MPNSTs), a “cold” tumor lacking immune cells, could sensitize the tumors to immune checkpoint blockade in both human and mouse MPNST models. This offers a potential treatment for this aggressive tumor for which no molecular therapy currently exists.

Read the full publication here.